Screener
Amneal Pharmaceuticals, Inc. AMRX Affordable Medicines — Cost of goods sold
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Amneal Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CostOfGoodsAndServicesSold.
The source filing: Amneal Pharmaceuticals, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 5:19 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001723128-26-000031
| Three Months Ended June 30, 2026 | Affordable Medicines (1) | Specialty | Av KARE | Corporateand Other | Total Company |
|---|---|---|---|---|---|
| Net revenue | $489,913 | $149,295 | $156,989 | — | $796,197 |
| Cost of goods sold | 282,684 | 48,265 | 130,740 | — | 461,689 |
| Gross profit | 207,229 | 101,030 | 26,249 | — | 334,508 |
| Selling, general and administrative | 42,367 | 40,095 | 16,913 | 49,347 | 148,722 |
| Research and development | 33,023 | 5,994 | — | — | 39,017 |
| Intellectual property legal development expenses | 2,002 | 85 | — | — | 2,087 |
| Acquisition costs | — | — | — | 7,600 | 7,600 |
| Restructuring and other charges | — | — | — | 554 | 554 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Amneal Pharmaceuticals, Inc.'s affordable medicines — cost of goods sold?
- Amneal Pharmaceuticals, Inc. (AMRX) reported affordable medicines — cost of goods sold of $282.68M in Q2 2026.
- How has Amneal Pharmaceuticals, Inc.'s affordable medicines — cost of goods sold changed year-over-year?
- Amneal Pharmaceuticals, Inc.'s affordable medicines — cost of goods sold increased by 11.9% year-over-year, from $252.65M to $282.68M.
- What is the long-term trend for Amneal Pharmaceuticals, Inc.'s affordable medicines — cost of goods sold?
- Over 3 years (2022 to 2025), Amneal Pharmaceuticals, Inc.'s affordable medicines — cost of goods sold has grown at a 5.8% compound annual growth rate (CAGR), from $896.03M to $1.06B.
- What does affordable medicines — cost of goods sold mean?
- Includes the direct costs attributable to the production of the pharmaceutical products sold within the Affordable Medicines segment, such as raw materials, manufacturing labor, and overhead. Monitoring this metric is essential for evaluating the segment's production efficiency and supply chain cost management.
Ask your AI about Amneal Pharmaceuticals, Inc.'s affordable medicines — cost of goods sold.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude